CALA (CALA) Stock Price & Analysis
CALA (CALA) rose 0.00% to USD 0 as of July 25, 2026 at 06:11 UTC, according to Nexqual real-time market data.
CALA last closed at USD 0; the session ranged USD 0–0 on volume of 315 shares. Market capitalization is $1,461, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, July 25, 2026 at 06:11 UTC.
Key Statistics (as of July 25, 2026 at 06:11 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 315 shares |
| Market Cap | $1,461 |
| Exchange | PNK |
Technical Analysis (CALA)
Nexqual's technical model rates CALA "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of July 25, 2026 at 06:11 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.75 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (CALA)
Wall Street analysts rate CALA "None", per Nexqual as of July 25, 2026 at 06:11 UTC.
| Consensus Rating | None |
|---|
Earnings (CALA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2022-09-30 | USD -1.92 vs est -1.95 ▲ beat |
| 2022-06-30 | USD -1.98 vs est -2.66 ▲ beat |
| 2022-03-31 | USD -3.6 vs est -3.3 ▼ miss |
| 2021-12-31 | USD -18.4 vs est -4.4 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Financials & Fundamentals (CALA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -114.14% |
| Debt / Equity | 8.17 |
| Current Ratio | 3.6 |
| Total Cash | $25.45M |
| Total Debt | $1.67M |
| Free Cash Flow | $-28.17M |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Financial Health Score (CALA)
Nexqual rates CALA's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $25M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$28M, burning cash |
| Efficiency | Critical — ROE -114%, ROA -56.3% |
Ownership (CALA)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 4.87M |
| Float | 4.83M |
| Short % of Float | +8.92% |
Source: Nexqual, July 25, 2026 at 06:11 UTC.
Leadership (CALA)
CALA is led by Stephanie Wong (age 50), CFO & Secretary, per Nexqual as of July 25, 2026 at 06:11 UTC.
| CFO & Secretary | Stephanie Wong (age 50) |
|---|---|
| Senior Vice President of Development | Christopher J. Molineaux (age 72) |
| Senior Vice President of Research | Frank Parlati (age 56) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SYRS | Syros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| AFMDQ | Affimed N.V. | USD 0 | ▲ 0% |
| CBIO | Crescent Biopharma, Inc. | USD 16.3 | ▲ 2.97% |
| AKBA | Akebia Therapeutics, Inc. | USD 1.22 | ▼ 3.17% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:11 UTC. This page is informational and not investment advice.